المؤلفون: von Arx, C., Della Vittoria Scarpati, G., Cannella, L., Clemente, O., Marretta, A.L., Bracigliano, A., Picozzi, F., Iervolino, D., Granata, V., Modica, R., Bianco, A., Mocerino, C., Di Mauro, A., Pizzolorusso, A., Di Sarno, A., Ottaiano, A., Tafuto, S.

المصدر: ESMO Open ; volume 9, issue 5, page 103003 ; ISSN 2059-7029

الإتاحة: https://doi.org/10.1016/j.esmoop.2024.103003Test
https://api.elsevier.com/content/article/PII:S2059702924007713?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2059702924007713?httpAccept=text/plainTest

المؤلفون: Di Mauro, A., Scognamiglio, G., Cerrone, M., Rega, R.A., Clemente, O., Mignogna, C., Cannella, L., Pizzolorusso, A., Picozzi, F., Cantile, M., Moccia, P., Iervolino, D., De Chiara, A., Ferrara, G., Tafuto, S.

المصدر: ESMO Open ; volume 9, page 102487 ; ISSN 2059-7029

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1016/j.esmoop.2024.102487Test
https://api.elsevier.com/content/article/PII:S2059702924002552?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2059702924002552?httpAccept=text/plainTest

المؤلفون: Ottaviano, M, Curvietto, M, Rescigno, P, Tortora, M, Palmieri, G, Giannarelli, D, Aieta, M, Assalone, P, Attademo, L, Avallone, A, Bloise, F, Bosso, D, Borzillo, V, Buono, G, Calderoni, G, Caputo, F, Cartenì, G, Cavallero, D, Cavo, A, Ciardiello, F, Conca, R, Conteduca, V, De Falco, S, De Felice, M, De Laurentiis, M, De Placido, P, De Placido, S, De Santo, I, De Stefano, A, Della Corte, CM, Di Franco, R, Di Lauro, V, Fabbrocini, A, Federico, P, Festino, L, Giordano, P, Giuliano, M, Gridelli, C, Grimaldi, AM, Lia, M, Marretta, AL, Massa, V, Mennitto, A, Merler, S, Merz, V, Messina, C, Messina, M, Milano, M, Minisini, AM, Montesarchio, V, Morabito, A, Morgillo, F, Mucci, B, Nappi, L, Napolitano, F, Paciolla, I, Pagliuca, M, Parola, S, Pepe, S, Petrillo, A, Piantedosi, F, Piccin, L, Picozzi, F, Pietroluongo, E, Pignata, S, Prati, V, Riccio, V, Rosanova, M, Rossi, A, Russo, A, Salati, M, Santabarbara, G, Sbrana, A, Simeone, E, Silvestri, A, Spada, M, Tarantino, P, Taveggia, P, Tomei, F, Vincenzo, T, Trapani, D, Trojanello, C, Vanella, V, Vari, S, Ventriglia, J, Vitale, MG, Vitiello, F, Vivaldi, C, von Arx, C, Zacchi, F, Zampiva, I, Zivi, A, Daniele, B, Ascierto, PA, SCITO (Società Campana di ImmunoTerapia Oncologica)

المساهمون: Rescigno, Pasquale

مصطلحات موضوعية: SCITO (Società Campana di ImmunoTerapia Oncologica), Humans, Pneumonia, Viral, Coronavirus Infections, Neoplasms, Prevalence, Medical Oncology, Infection Control, Geography, Adult, Italy, Female, Male, Drug Prescriptions, Pandemics, CTLA-4 Antigen, Programmed Cell Death 1 Receptor, Time-to-Treatment, Surveys and Questionnaires, Practice Patterns, Physicians', Oncologists, Betacoronavirus, Antineoplastic Agents, Immunological, B7-H1 Antigen, COVID-19, SARS-CoV-2

الوصف: BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the health systems worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune checkpoint inhibitors (ICIs) are lacking. We depicted the practice and adaptations in the management of patients with solid tumors eligible or receiving ICIs during the COVID-19 pandemic, with a special focus on Campania region. METHODS: This survey (25 questions), promoted by the young section of SCITO (Società Campana di ImmunoTerapia Oncologica) Group, was circulated among Italian young oncologists practicing in regions variously affected by the pandemic: high (group 1), medium (group 2) and low (group 3) prevalence of SARS-CoV-2-positive patients. For Campania region, the physician responders were split into those working in cancer centers (CC), university hospitals (UH) and general hospitals (GH). Percentages of agreement, among High (H) versus Medium (M) and versus Low (L) group for Italy and among CC, UH and GH for Campania region, were compared by using Fisher's exact tests for dichotomous answers and χ2 test for trends relative to the questions with 3 or more options. RESULTS: This is the first Italian study to investigate the COVID-19 impact on cancer immunotherapy, unique in its type and very clear in the results. The COVID-19 pandemic seemed not to affect the standard practice in the prescription and delivery of ICIs in Italy. Telemedicine was widely used. There was high consensus to interrupt immunotherapy in SARS-CoV-2-positive patients and to adopt ICIs with longer schedule interval. The majority of the responders tended not to delay the start of ICIs; there were no changes in supportive treatments, but some of the physicians opted for delaying surgeries (if part of patients' planned treatment approach). The results from responders in Campania did not differ significantly from the national ones. CONCLUSION: Our study highlights the efforts of Italian oncologists to maintain high standards of care ...

وصف الملف: Print; application/pdf

العلاقة: Journal for immunotherapy of cancer, 2020, 8 (2); https://repository.icr.ac.uk/handle/internal/4346Test

الإتاحة: https://doi.org/10.1136/jitc-2020-001154Test
https://repository.icr.ac.uk/handle/internal/4346Test

المؤلفون: Ottaviano, M., Giuliano, M., Tortora, M., La Civita, E., Liotti, A., Longo, M., Bruzzese, D., Cennamo, M., Riccio, V., De Placido, P., Picozzi, F., Parola, S., Daniele, B., Botti, G., Formisano, P., Beguinot, F., De Placido, S., Terracciano, D., Palmieri, G.

المصدر: Journal of Thoracic Oncology ; volume 16, issue 3, page S155 ; ISSN 1556-0864

مصطلحات موضوعية: Pulmonary and Respiratory Medicine, Oncology

الإتاحة: https://doi.org/10.1016/j.jtho.2021.01.180Test
https://api.elsevier.com/content/article/PII:S1556086421002227?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1556086421002227?httpAccept=text/plainTest

المؤلفون: Palmieri, G., Giuliano, M., Tortora, M., Formisano, P., Marretta, A., D'Esposito, V., Malfitano, A.M., Parola, S., Picozzi, F., Riccio, V., Di Somma, S., De Placido, P., Mucci, B., Pietroluongo, E., Santomauro, M.A., Daniele, B., De Placido, S., Ottaviano, M.

المصدر: Journal of Thoracic Oncology ; volume 16, issue 3, page S155-S156 ; ISSN 1556-0864

مصطلحات موضوعية: Pulmonary and Respiratory Medicine, Oncology

الإتاحة: https://doi.org/10.1016/j.jtho.2021.01.181Test
https://api.elsevier.com/content/article/PII:S1556086421002239?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1556086421002239?httpAccept=text/plainTest

المؤلفون: Ottaviano, M., Giuliano, M., Tortora, M., Picozzi, F., Mucci, B., Parola, S., Riccio, V., Pietroluongo, E., De Placido, P., Vaia, A., D'Esposito, V., Malfitano, A.M., Di Somma, S., Campione, S., Staibano, S., Botti, G., Formisano, P., Daniele, B., De Placido, S., Palmieri, G.

المصدر: Annals of Oncology ; volume 31, page S1079 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2020.08.1444Test
https://api.elsevier.com/content/article/PII:S0923753420414401?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753420414401?httpAccept=text/plainTest

المؤلفون: Clemente, O., Starita, N., Bracigliano, A., Cives, M., Tatangelo, F., Barretta, M.L., Badalamenti, G., Lastoria, S., Picozzi, F., Di Mauro, A., von Arx, C., Cannella, L., Tafuto, S.

المصدر: Annals of Oncology ; volume 34, page S708 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2023.09.733Test
https://api.elsevier.com/content/article/PII:S0923753423015697?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753423015697?httpAccept=text/plainTest

المؤلفون: von Arx, C., Cannella, L., Marretta, A.L., Bracigliano, A., Tatangelo, F., Clemente, O., Iervolino, D., Granata, V., Mocerino, C., Modica, R., Pizzolorusso, A., Bianco, A., Picozzi, F., Di Sarno, A., Tafuto, S.

المصدر: Annals of Oncology ; volume 34, page S708-S709 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2023.09.735Test
https://api.elsevier.com/content/article/PII:S0923753423015715?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753423015715?httpAccept=text/plainTest

المؤلفون: Baldi G. G., Lo Vullo S., Grignani G., Vincenzi B., Badalamenti G., Mastore M., Buonomenna C., Morosi C., Barisella M., Frezza A. M., Provenzano S., Simeone N., Picozzi F., Mariani L., Casali P. G., Stacchiotti S.

المساهمون: Baldi G.G., Lo Vullo S., Grignani G., Vincenzi B., Badalamenti G., Mastore M., Buonomenna C., Morosi C., Barisella M., Frezza A.M., Provenzano S., Simeone N., Picozzi F., Mariani L., Casali P.G., Stacchiotti S.

مصطلحات موضوعية: bone sarcoma, chemotherapy, chordoma, cisplatin, imatinib, systemic treatment

الوصف: Background: To report on a retrospective case-series analysis of weekly cisplatin (wCDDP) as a single agent or combined with imatinib (wCDDP/I) in patients with advanced chordoma treated within the Italian Rare Cancer Network. Methods: Adult patients with a diagnosis of advanced, brachyury-positive chordoma, treated from April 2007 to October 2020 with wCDDP or wCDDP/I were retrospectively identified. Imatinib was withheld at the same time as wCDDP. Response according to Response Evaluation Criteria in Solid Tumors, overall survival (OS), and progression-free survival (PFS) were analyzed. Results: Thirty-three consecutive patients were identified (wCDDP as front-line n = 8 [24.2%]; wCDDP as a further line n = 25 [75.8%]; prior imatinib n = 25 [75.8%]; evidence of progression before starting wCDDP n = 33). Of 32 patients evaluable for response (wCDDP, n = 22 [68.8%]; wCDDP/I, n = 10 [31.3%]), best response was stable disease (SD) in 27 patients (84.3%) and progression in 5 patients (15.6%). At a median follow-up of 54 months, the median OS (m-OS) was 30.3 months (interquartile range [IQR], 18.1-56.6), the m-PFS was 8.0 months (IQR, 5.1-17.0), the 6-month PFS rate was 65.2%, and the 12-month PFS rate was 30.3%. Of 22 patients who received wCDDP, the best response was SD in 18 patients (81.8%) and progression in 4 patients (18.2%), and the m-PFS was 8.0 months (IQR, 5.1-17.0 months). Of 10 patients who received treatment with wCDDP/I, the best response was SD in 9 patients (90%) and progression in 1 patient (10%), and the m-PFS was 9.3 months (IQR, 4.9-26.5 months). Conclusions: This series suggests that wCDDP, both as a single agent and combined with imatinib, has antitumor activity in chordoma. Although no dimensional responses were observed, 65% and 30% of previously progressive patients were progression-free at 6 and 12 months, respectively. A prospective study is warranted.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/35026050; info:eu-repo/semantics/altIdentifier/wos/WOS:000742156000001; numberofpages:10; journal:CANCER; http://hdl.handle.net/10447/534639Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85122828296

الإتاحة: https://doi.org/10.1002/cncr.34083Test
http://hdl.handle.net/10447/534639Test

المؤلفون: Ottaviano M., Curvietto M., Rescigno P., Tortora M., Palmieri G., Giannarelli D., Aieta M., Assalone P., Attademo L., Avallone A., Bloise F., Bosso D., Borzillo V., Buono G., Calderoni G., Caputo F., Carteni G., Cavallero D., Cavo A., Ciardiello F., Conca R., Conteduca V., De Falco S., De Felice M., De Laurentiis M., De Placido P., De Placido S., De Santo I., De Stefano A., Della Corte C. M., Di Franco R., Di Lauro V., Fabbrocini A., Federico P., Festino L., Giordano P., Giuliano M., Gridelli C., Grimaldi A. M., Lia M., Marretta A. L., Massa V., Mennitto A., Merler S., Merz V., Messina C., Messina M., Milano M., Minisini A. M., Montesarchio V., Morabito A., Morgillo F., Mucci B., Nappi L., Napolitano F., Paciolla I., Pagliuca M., Parola S., Pepe S., Petrillo A., Piantedosi F., Piccin L., Picozzi F., Pietroluongo E., Pignata S., Prati V., Riccio V., Rosanova M., Rossi A., Russo A., Salati M., Santabarbara G., Sbrana A., Simeone E., Silvestri A., Spada M., Tarantino P., Taveggia P., Tomei F., Vincenzo T., Trapani D., Trojanello C., Vanella V., Vari S., Ventriglia J., Vitale M. G., Vitiello F., Vivaldi C., Von Arx C., Zacchi F., Zampiva I., Zivi A., Daniele B., Ascierto P. A.

المساهمون: Ottaviano, M., Curvietto, M., Rescigno, P., Tortora, M., Palmieri, G., Giannarelli, D., Aieta, M., Assalone, P., Attademo, L., Avallone, A., Bloise, F., Bosso, D., Borzillo, V., Buono, G., Calderoni, G., Caputo, F., Carteni, G., Cavallero, D., Cavo, A., Ciardiello, F., Conca, R., Conteduca, V., De Falco, S., De Felice, M., De Laurentiis, M., De Placido, P., De Placido, S., De Santo, I., De Stefano, A., Della Corte, C. M., Di Franco, R., Di Lauro, V., Fabbrocini, A., Federico, P., Festino, L., Giordano, P., Giuliano, M., Gridelli, C., Grimaldi, A. M., Lia, M., Marretta, A. L., Massa, V., Mennitto, A., Merler, S., Merz, V., Messina, C., Messina, M., Milano, M., Minisini, A. M., Montesarchio, V., Morabito, A., Morgillo, F., Mucci, B., Nappi, L., Napolitano, F., Paciolla, I., Pagliuca, M., Parola, S., Pepe, S., Petrillo, A., Piantedosi, F., Piccin, L., Picozzi, F., Pietroluongo, E., Pignata, S., Prati, V., Riccio, V., Rosanova, M., Rossi, A., Russo, A., Salati, M., Santabarbara, G., Sbrana, A., Simeone, E., Silvestri, A., Spada, M., Tarantino, P., Taveggia, P., Tomei, F., Vincenzo, T., Trapani, D., Trojanello, C., Vanella, V., Vari, S., Ventriglia, J., Vitale, M. G., Vitiello, F., Vivaldi, C., Von Arx, C., Zacchi, F., Zampiva, I., Zivi, A., Daniele, B., Ascierto, P. A.

مصطلحات موضوعية: antineoplastic protocol, healthcare economics and organization, immunotherapy, lung neoplasm, melanoma, Adult, Antineoplastic Agents, Immunological, B7-H1 Antigen, Betacoronaviru, COVID-19, CTLA-4 Antigen, Coronavirus Infection, Drug Prescription, Female, Geography, Human, Infection Control, Italy, Male, Medical Oncology, Neoplasm, Oncologist, Pandemic, Pneumonia, Viral, Practice Patterns, Physicians', Prevalence, Programmed Cell Death 1 Receptor

الوصف: Background The coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the health systems worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune checkpoint inhibitors (ICIs) are lacking. We depicted the practice and adaptations in the management of patients with solid tumors eligible or receiving ICIs during the COVID-19 pandemic, with a special focus on Campania region. Methods This survey (25 questions), promoted by the young section of SCITO (Società Campana di ImmunoTerapia Oncologica) Group, was circulated among Italian young oncologists practicing in regions variously affected by the pandemic: high (group 1), medium (group 2) and low (group 3) prevalence of SARS-CoV-2-positive patients. For Campania region, the physician responders were split into those working in cancer centers (CC), university hospitals (UH) and general hospitals (GH). Percentages of agreement, among High (H) versus Medium (M) and versus Low (L) group for Italy and among CC, UH and GH for Campania region, were compared by using Fisher's exact tests for dichotomous answers and χ 2 test for trends relative to the questions with 3 or more options. Results This is the first Italian study to investigate the COVID-19 impact on cancer immunotherapy, unique in its type and very clear in the results. The COVID-19 pandemic seemed not to affect the standard practice in the prescription and delivery of ICIs in Italy. Telemedicine was widely used. There was high consensus to interrupt immunotherapy in SARS-CoV-2-positive patients and to adopt ICIs with longer schedule interval. The majority of the responders tended not to delay the start of ICIs; there were no changes in supportive treatments, but some of the physicians opted for delaying surgeries (if part of patients' planned treatment approach). The results from responders in Campania did not differ significantly from the national ones. Conclusion Our study highlights the efforts of Italian oncologists to maintain high standards of care ...

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33060148; info:eu-repo/semantics/altIdentifier/wos/WOS:000583157800005; volume:8; firstpage:e001154; lastpage:e001154; journal:JOURNAL FOR IMMUNOTHERAPY OF CANCER; http://hdl.handle.net/11386/4756291Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85093476336

الإتاحة: https://doi.org/10.1136/jitc-2020-001154Test
http://hdl.handle.net/11386/4756291Test